BR112015024764A2 - oligonucleotídeos de tgf-beta modificados - Google Patents
oligonucleotídeos de tgf-beta modificadosInfo
- Publication number
- BR112015024764A2 BR112015024764A2 BR112015024764A BR112015024764A BR112015024764A2 BR 112015024764 A2 BR112015024764 A2 BR 112015024764A2 BR 112015024764 A BR112015024764 A BR 112015024764A BR 112015024764 A BR112015024764 A BR 112015024764A BR 112015024764 A2 BR112015024764 A2 BR 112015024764A2
- Authority
- BR
- Brazil
- Prior art keywords
- tgf
- nucleic acid
- acid sequence
- oligonucleotide
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
Abstract
abstract the invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the tgf-beta1, tgf-beta2 or tgf-beta3 nucleic acid sequence, which comprises modified nucleotides such as lna, ena, polyalkylene oxide-, 2'-fluoro, 2'-o-methoxy and/or 2'-o-methyl modified nucleotides. the selected regions are preferably the region of nucleic acid no. 1380 to 1510, no. 1660 to 1680, no. 2390 to 2410, or no. 2740 to 2810 of the tgf-beta2 nucleic acid sequence of seq id no. 1, specific regions of the tgf-beta1 nucleic acid sequence of seq id no. 149, or specific regions of the tgf-beta3 nucleic acid sequence of seq id no. 267. the invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in the prevention and/or treatment of a malignant and/or benign tumor, an immunologic disease, fibrosis, glaucoma, etc.. tradução resumo resumo patente de invenção: "oligonucleotídeos de tgf-beta modificados". a invenção refere-se a um oligonucleotídeo consistindo em 10 a 20 nucleotídeos de regiões selecionadas da sequência ade ácidos nucleicos de tgf-beta1, tgf-beta2 ou tgf-beta3, que compreende nucleotídeos modificados tais como nucleotídeos lna, ena, polialquileno óxido-, 2'-flúor, 2'-o-metóxi e/ou 2'-o-metil modificados. as regiões selecionadas são de preferência a região de ácido nucleico n° 1380 a 1510, n° 1660 a 1680, n° 2390 a 2410, ou n° 2740 a 2810 da sequência de ácidos nucleicos de tgf-beta2 de seq id n° 1, regiões específicas da sequência de ácidos nucleicos de tgf-beta1 de seq id n° 149, ou regiões específicas da sequência de ácidos nucleicos de seq id n° 267. a invenção refere-se ainda a composições farmacêuticas compreendendo tal oligonucleotídeo, onde a composição ou o oligonucleotídeo é usado na prevenção e/ou no tratamento de um tumor maligno e/ou benigno, um doença imunológica, fibrose, glaucoma, etc.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161474 | 2013-03-27 | ||
| EP13161474.5 | 2013-03-27 | ||
| EP13173078.0 | 2013-06-20 | ||
| EP13173078 | 2013-06-20 | ||
| EP13199826.2 | 2013-12-30 | ||
| EP13199826 | 2013-12-30 | ||
| EP2014154835 | 2014-10-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015024764A2 true BR112015024764A2 (pt) | 2017-10-24 |
| BR112015024764B1 BR112015024764B1 (pt) | 2022-06-28 |
Family
ID=50390096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015024764-4A BR112015024764B1 (pt) | 2013-03-27 | 2014-03-27 | Oligonucleotídeos de tgf-beta modificados, seu uso e composições farmacêuticas que os compreendem |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9926563B2 (pt) |
| EP (1) | EP2978845B8 (pt) |
| JP (1) | JP6492053B2 (pt) |
| KR (1) | KR102108599B1 (pt) |
| CN (2) | CN105378083B (pt) |
| BR (1) | BR112015024764B1 (pt) |
| CA (1) | CA2908096C (pt) |
| DK (1) | DK2978845T3 (pt) |
| EA (1) | EA201591590A1 (pt) |
| ES (1) | ES2808862T3 (pt) |
| HK (1) | HK1221253A1 (pt) |
| PL (1) | PL2978845T3 (pt) |
| PT (1) | PT2978845T (pt) |
| WO (1) | WO2014154835A2 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| KR20180103817A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 암을 치료하기 위한 조성물과 방법 |
| KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
| MA45469A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
| MA45471A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations |
| MA45340A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques du récepteur des androgènes et leurs utilisations |
| MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| MA45470A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques kras et leurs utilisations |
| MA45349A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques egfr et leurs utilisations |
| MA45468A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques myc et utilisations |
| WO2018087359A1 (en) * | 2016-11-11 | 2018-05-17 | Isarna Therapeutics Gmbh | Tgf-beta oligonucleotide for use in treatment of ophthalmic diseases |
| KR20240007965A (ko) | 2017-12-06 | 2024-01-17 | 어비디티 바이오사이언시스 인크. | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 |
| EP4121063A4 (en) | 2020-03-19 | 2024-07-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS FOR TREATING FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| KR20220039639A (ko) * | 2020-09-21 | 2022-03-29 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
| CN113073082A (zh) * | 2021-03-19 | 2021-07-06 | 广州远想生物科技有限公司 | TGF-β3间充质干细胞外泌体及其制备方法和应用 |
| WO2023043953A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| CN118251490A (zh) * | 2021-11-01 | 2024-06-25 | 奥托泰利克生物公司 | 反义寡核苷酸 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309406A (en) | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| EP1160319A3 (en) | 1993-04-30 | 2002-03-06 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (TGF-beta) |
| WO1994025588A2 (en) | 1993-04-30 | 1994-11-10 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) |
| US20050287128A1 (en) | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
| JP2005517423A (ja) | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | 短干渉核酸（ｓｉＮＡ）を用いるＴＧＦ−ベータおよびＴＧＦ−ベータレセプター遺伝子の発現のＲＮＡ干渉媒介性阻害 |
| US20040006030A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
| SI2264172T1 (sl) | 2002-04-05 | 2017-12-29 | Roche Innovation Center Copenhagen A/S | Oligomerne spojine za modulacijo izražanja HIF-1alfa |
| JP4476594B2 (ja) * | 2003-10-17 | 2010-06-09 | 淳二 城戸 | 有機エレクトロルミネッセント素子 |
| DK1706489T3 (da) | 2003-12-23 | 2010-09-13 | Santaris Pharma As | Oligomer forbindelser for modulationen af BCL-2 |
| AU2005218759B2 (en) | 2004-02-27 | 2009-07-16 | Antisense Pharma Gmbh | Pharmaceutical composition |
| EP1568383A3 (en) * | 2004-02-27 | 2005-11-16 | Antisense Pharma GmbH | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
| EP1935428A1 (en) | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
| US8268793B2 (en) | 2007-05-11 | 2012-09-18 | Santaris Pharma A/S | RNA antagonist compounds for the modulation of HER3 |
| WO2010006973A2 (en) * | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of tgf-beta receptor genes |
| JP2013531981A (ja) | 2010-06-11 | 2013-08-15 | アンチセンス・ファーマ・ゲーエムベーハー | 選択的オリゴヌクレオチド修飾の方法 |
| EP2453017A1 (en) | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
| EA201492122A1 (ru) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии utrn |
-
2014
- 2014-03-27 JP JP2016504682A patent/JP6492053B2/ja active Active
- 2014-03-27 BR BR112015024764-4A patent/BR112015024764B1/pt active IP Right Grant
- 2014-03-27 PL PL14713467T patent/PL2978845T3/pl unknown
- 2014-03-27 CN CN201480030886.2A patent/CN105378083B/zh active Active
- 2014-03-27 CN CN201810927516.9A patent/CN109234274B/zh active Active
- 2014-03-27 EP EP14713467.0A patent/EP2978845B8/en active Active
- 2014-03-27 KR KR1020157030780A patent/KR102108599B1/ko active IP Right Grant
- 2014-03-27 US US14/780,043 patent/US9926563B2/en active Active
- 2014-03-27 ES ES14713467T patent/ES2808862T3/es active Active
- 2014-03-27 DK DK14713467.0T patent/DK2978845T3/da active
- 2014-03-27 PT PT147134670T patent/PT2978845T/pt unknown
- 2014-03-27 CA CA2908096A patent/CA2908096C/en active Active
- 2014-03-27 EA EA201591590A patent/EA201591590A1/ru unknown
- 2014-03-27 WO PCT/EP2014/056221 patent/WO2014154835A2/en active Application Filing
-
2016
- 2016-08-03 HK HK16109276.8A patent/HK1221253A1/zh unknown
-
2018
- 2018-01-29 US US15/882,221 patent/US10538768B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014154835A3 (en) | 2014-11-20 |
| KR102108599B1 (ko) | 2020-05-08 |
| CN109234274B (zh) | 2021-09-21 |
| PT2978845T (pt) | 2020-08-03 |
| CA2908096A1 (en) | 2014-10-02 |
| EP2978845A2 (en) | 2016-02-03 |
| HK1221253A1 (zh) | 2017-05-26 |
| CN105378083B (zh) | 2018-09-21 |
| WO2014154835A2 (en) | 2014-10-02 |
| CN109234274A (zh) | 2019-01-18 |
| US20160076037A1 (en) | 2016-03-17 |
| CN105378083A (zh) | 2016-03-02 |
| US10538768B2 (en) | 2020-01-21 |
| EP2978845B8 (en) | 2020-06-17 |
| KR20150140701A (ko) | 2015-12-16 |
| EA201591590A1 (ru) | 2016-05-31 |
| US20180230473A1 (en) | 2018-08-16 |
| BR112015024764B1 (pt) | 2022-06-28 |
| JP6492053B2 (ja) | 2019-03-27 |
| DK2978845T3 (da) | 2020-08-10 |
| ES2808862T3 (es) | 2021-03-02 |
| US9926563B2 (en) | 2018-03-27 |
| CA2908096C (en) | 2022-05-03 |
| JP2016515385A (ja) | 2016-05-30 |
| PL2978845T3 (pl) | 2020-11-16 |
| EP2978845B1 (en) | 2020-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015024764A2 (pt) | oligonucleotídeos de tgf-beta modificados | |
| EA200870402A1 (ru) | Фармацевтическая композиция | |
| EA201100810A1 (ru) | Фармацевтическая композиция | |
| BR112013005872A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| NZ730296A (en) | Modified double-stranded rna agents | |
| NZ797319A (en) | Modified rnai agents | |
| BR112015024729A8 (pt) | oligonucleotídeos tgf-beta2 modificados | |
| MX2013009191A (es) | Oligonucleotidos antisentido. | |
| BR112014025020A2 (pt) | composições e métodos para inibição da expressão do gene alas1 | |
| MX2013005875A (es) | Inhibidores de microarn que comprenden nucleotidos bloqueados. | |
| CL2012000021A1 (es) | Composiciones de oligonucleótidos; oligonucleótidos; composiciones farmacéuticas que contienen las composiciones; y uso de las composiciones de oligonucleótidos en el tratamiento del cáncer, tal como cáncer pancreático | |
| MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
| PE20210921A1 (es) | Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden | |
| EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| MD20150006A2 (ro) | Inhibitori de micro-ARN din familia miR-15 | |
| IN2014DN10390A (pt) | ||
| TN2015000079A1 (en) | Antisense polynucleotides to induce exon skipping and methods of treating dystrophies | |
| MX2018002998A (es) | Derivado de acido nucleico que tiene actividad inmunoestimuladora. | |
| EA201790867A1 (ru) | Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7 | |
| RU2015129287A (ru) | Апоптоз-индуцирующее средство | |
| MX2019005101A (es) | Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. | |
| WO2015032800A3 (en) | Compositions and methods for inducing senescence in cancer cells | |
| BR112015022308A8 (pt) | oligonucleotídeos antissenso para o tratamento de células-tronco cancerosas | |
| MX2018006445A (es) | Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/03/2014, OBSERVADAS AS CONDICOES LEGAIS |